Advanced Renal Cell Carcinoma- Pipeline Insight, 2024

Advanced Renal Cell Carcinoma- Pipeline Insight, 2024

DelveInsight’s, “Advanced Renal Cell Carcinoma- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Advanced Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Advanced Renal Cell Carcinoma: Understanding

Advanced Renal Cell Carcinoma: Overview

According to the Centers for Disease Control and Prevention (CDC) Trusted Source, Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. This type of cancer develops in the lining of very small tubes, or tubules, inside the kidney. These tubules help to remove waste products from the blood. Stage 4 RCC is the most advanced stage where the disease has spread from the kidneys to one or more distant areas of the body. According to a 2016 study Trusted Source, the outlook for advanced RCC depends largely on where the new tumors are growing in the body. For example, people with RCC that has spread to the pancreas have a higher overall survival rate than those where cancer has spread to the brain, bones, or liver.

The proximal renal tubular epithelium is the kidney tissue from which RCC arises. The two forms are sporadic: nonhereditary and hereditary. The structural alterations of both forms occur on the short arm of chromosome 3 (3p). Families at high risk for developing renal cancer were studied, which led to the cloning of genes. The genes whose alteration resulted in RCC formation were tumor suppressors (VHL, TSC) or oncogenes (MET).

People with RCC typically do not experience any symptoms during the early stages of the disease. Symptoms may only become apparent as the disease progresses. The ACS Trusted Source advises people to see a doctor if they experience any of the symptoms such as blood in the urine, persistent pain on one side of the lower back, a lump on the side or abdomen, general fatigue, unexplained weight loss, anemia, and others. Doctors may recommend imaging tests to confirm the cancer and determine whether and to what extent it has spread.

Advanced RCC is very difficult to cure. However, the Kidney Cancer Association (KCA) notes that new treatments are continually emerging and gaining FDA approval. According to the ACS Trusted Source, systemic therapy with or without surgery is the mainstay treatment for stage 4 RCC. Systemic therapy may consist of two immunotherapy drugs, a targeted therapy drug with an immunotherapy drug, or a targeted therapy drug alone. According to a 2021 study, immunotherapy drugs can significantly improve outcomes in people with RCC. Such drugs include: i) Vascular endothelial growth factor inhibitors (anti-VEGFs): These restrict the blood supply to the cancer. ii) Immune checkpoint inhibitors: These help the person’s own immune system recognize and attack cancer cells.

Another class of drugs that may successfully treat RCC is tyrosine kinase inhibitors (TKIs). These medications inhibit the production of enzymes that cancer cells require for growth. Despite many recent drug approvals for renal cell cancer (RCC), there remains a pressing must identify new therapeutic targets. Finally, other systemic therapy or supportive care approaches must be considered for special patient populations such as those with poor performance status, end-organ dysfunction, brain metastases, or who have undergone metastasectomy.

""Advanced Renal Cell Carcinoma- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Advanced Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Renal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Renal Cell Carcinoma.

Advanced Renal Cell Carcinoma Emerging Drugs Chapters

This segment of the Advanced Renal Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced Renal Cell Carcinoma Emerging Drugs

• Belzutifan: Merck Sharp & Dohme

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α). Belzutifan binds to HIF-2α, and in conditions of hypoxia or impairment of VHL protein function, belzutifan inhibits the HIF-2α-HIF-1β interaction, leading to reduced transcription and expression of HIF-2α target genes. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of advanced renal cell carcinoma.

• IPI-549: Infinity Pharmaceuticals

Eganelisib is a first-in-class, oral, once-daily, immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). Selective PI3K-gamma inhibition represents a unique and potentially transformative approach within immuno-oncology (I/O), and IPI-549 has the potential to be a first-in-class therapy. Preclinical research conducted by Infinity and academic collaborators demonstrates that IPI-549 works by reprogramming key immune suppressive cells (called M2 macrophages or myeloid derived suppressor cells (MDSCs)) within the tumor microenvironment from a pro-tumor function to an anti-tumor function, decreasing immune suppression and increasing immune activation, ultimately leading to the activation and proliferation of T cells that can attack cancer cells. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of advanced renal cell carcinoma.

• JANX008: Janux Therapeutics

JANX008 is an EGFR-TRACTr that is designed to overcome CRS and known on-target EGFR healthy tissue toxicities. Epidermal growth factor receptor (EGFR) is a clinically validated target highly expressed on many solid tumors that are being underserved by current therapies. JANX008 targets EGFR for the treatment of multiple solid cancers including, but not limited to, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of advanced renal cell carcinoma.

Further product details are provided in the report……..

Advanced Renal Cell Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Advanced Renal Cell Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Advanced Renal Cell Carcinoma
• There are approx. 50+ key companies which are developing the therapies for Advanced Renal Cell Carcinoma. The companies which have their Advanced Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Merck Sharp & Dohme.
• Phases

DelveInsight’s report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced Renal Cell Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Renal Cell Carcinoma drugs.

Advanced Renal Cell Carcinoma Report Insights

• Advanced Renal Cell Carcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Advanced Renal Cell Carcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced Renal Cell Carcinoma drugs?
• How many Advanced Renal Cell Carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Renal Cell Carcinoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Renal Cell Carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced Renal Cell Carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck Sharp & Dohme
• Chia Tai Tianqing Pharmaceutical
• Hoffmann-La Roche
• CoImmune
• Infinity Pharmaceuticals
• NiKang Therapeutics
• Molecure S.A.
• Daiichi Sankyo
• Janux Therapeutics
• MedImmune
• Eli Lilly and Company
• Jiangsu HengRui Medicine Co., Ltd.
• Allogene Therapeutics
• Chongqing Precision Biotech Co., Ltd
• Pfizer
• Exelixis
• BeiGene
• Xencor

Key Products

• TQB2450
• Belzutifan
• Atezolizumab
• CMN-001
• IPI-549
• NKT2152
• OATD-02
• DS-6000a
• JANX008
• MEDI5752
• Abemaciclib
• SHR-1210
• ALLO-316
• CD70 CAR-T cells
• Selenomethionine
• XL092
• BGB-A445
• XmAb819